Chicago, Jan. 27, 2026 (GLOBE NEWSWIRE) -- The global viral vectors & plasmid DNA manufacturing market was valued at 4.21 billion in 2024 and is expected to reach US$ 20.30 billion by 2033, growing at ...
At a recent industry event, the 14th Annual Bioprocessing Summit in Boston, scientists discussed a variety of advances in gene therapy manufacturing. To learn more about these advances, GEN talked ...
DUBLIN--(BUSINESS WIRE)--The "Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034" report has been added to ResearchAndMarkets.com's offering. Overall world revenue for the viral vectors ...
The successes seen in a number of clinical studies on viral vector-based gene therapies (AAV, retroviral, and lentiviral vectors) are well documented, with an ever-broadening pipeline of products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results